BI 3819026
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 27, 2026
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim
First-in-human • New P1 trial • Oncology • Solid Tumor
April 16, 2026
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab
(clinicaltrialsregister.eu)
- P1 | N=12 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1